Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294475 | 1.00 | RAB9A (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL1226009 | 0.85 | MAPT (0.64) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL1226012 | 0.85 | MAPT (0.64) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL29871432 | 0.85 | MAPT (0.64) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL9799652 | 0.83 | MAPT (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL3209460 | 0.83 | RAB9A (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL9799655 | 0.83 | MAPT (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL3209446 | 0.83 | RAB9A (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL30963012 | 0.83 | MAPT (0.62) | RAB9AMAPK1MAPTNPC1CYP2A6 | |
| SCHEMBL10554653 | 0.81 | RAB9A (0.59) | RAB9AMAPK1MAPTNPC1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178040-A2 | INHIBITORS OF EWS-FLI1 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-09-21 | — | — | WO | disclosed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| US-6660740-B1 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-12-09 | — | — | US | disclosed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | RAB9A 2713/4885MAPK1 792/4885MAPT 2491/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | RAB9A 2389/4885MAPK1 799/4885MAPT 2399/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | RAB9A 2389/4885MAPK1 799/4885MAPT 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.